Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care

Medical Oncology

Volumn 25, Issue 1, 2008, Pages 22-29

  Lönnroth, Christina ^a   Svensson, Marie ^a   Wang, Wenhua ^a   Körner, Ulla ^a   Daneryd, Peter ^a   Nilsson, Ola ^a   Lundholm, Kent ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; Erythropoietin; Erythropoietin receptor; Palliative care

Indexed keywords

ERYTHROPOIETIN RECEPTOR; INDOMETACIN; KI 67 ANTIGEN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN ALPHA;

ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; ANEMIA; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MORTALITY; NEOPLASM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASMS; PALLIATIVE CARE; RECEPTORS, ERYTHROPOIETIN;

EID: 42949130784     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-9001-7     Document Type: Article

References (41)

1. D. Cella 1998 Factors influencing quality of life in cancer patients: anemia and fatigue Semin Oncol 25 3 Suppl 7 43 6
2. FK Lin S Suggs CH Lin JK Browne R Smalling JC Egrie 1985 Cloning and expression of the human erythropoietin gene Proc Natl Acad Sci USA 82 22 7580 4
3. K Jacobs C Shoemaker R Rudersdorf SD Neill RJ Kaufman A Mufson 1985 Isolation and characterization of genomic and cDNA clones of human erythropoietin Nature 313 6005 806 10
4. JW. Fisher 2003 Erythropoietin: physiology and pharmacology update Exp Biol Med (Maywood) 228 1 1 14
5. P Daneryd E Svanberg U Korner E Lindholm R Sandstrom H Brevinge 1998 Protection of metabolic and exercise capacity in unselected weight- losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study Cancer Res 58 23 5374 9
6. TJ Littlewood E Bajetta JW Nortier E Vercammen B. Rapoport 2001 Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 11 2865 74
7. JL Gabrilove CS Cleeland RB Livingston B Sarokhan E Winer LH. Einhorn 2001 Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 11 2875 82
8. G Acs P Acs SM Beckwith RL Pitts E Clements K Wong 2001 Erythropoietin and erythropoietin receptor expression in human cancer Cancer Res 61 9 3561 5
9. MO Arcasoy K Amin AF Karayal SC Chou JA Raleigh MA Varia 2002 Functional significance of erythropoietin receptor expression in breast cancer Lab Invest 82 7 911 8
10. D Ribatti A Marzullo B Nico E Crivellato R Ria A. Vacca 2003 Erythropoietin as an angiogenic factor in gastric carcinoma Histopathology 42 3 246 50
11. Y Yasuda Y Fujita T Matsuo S Koinuma S Hara A Tazaki 2003 Erythropoietin regulates tumour growth of human malignancies Carcinogenesis 24 6 1021 9
12. V. Brower 2003 Erythropoietin may impair, not improve, cancer survival Nat Med 9 12 1439
13. S Batra N Perelman LR Luck H Shimada P. Malik 2003 Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival Lab Invest 83 10 1477 87
14. G Acs X Xu C Chu P Acs A. Verma 2004 Prognostic significance of erythropoietin expression in human endometrial carcinoma Cancer 100 11 2376 86
15. F Pajonk A Weil A Sommer R Suwinski M. Henke 2004 The erythropoietin-receptor pathway modulates survival of cancer cells Oncogene 23 55 8987 91
16. SM Kumar G Acs D Fang M Herlyn DE Elder X. Xu 2005 Functional erythropoietin autocrine loop in melanoma Am J Pathol 166 3 823 30
17. M Henke R Laszig C Rube U Schafer KD Haase B Schilcher 2003 Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 9392 1255 60
18. B Leyland-Jones V Semiglazov M Pawlicki T Pienkowski S Tjulandin G Manikhas 2005 Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study J Clin Oncol 23 25 5960 72
19. TG Eccles A Patel A Verma D Nicholson Y Lukes RM Tuttle 2003 Erythropoietin and the erythropoietin receptor are expressed by papillary thyroid carcinoma from children and adolescents. Expression of erythropoietin receptor might be a favorable prognostic indicator Ann Clin Lab Sci 33 4 411 22
20. MJ. Weiss 2003 New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications Oncologist 8 Suppl 3 18 29
21. F Farrell A. Lee 2004 The erythropoietin receptor and its expression in tumor cells and other tissues Oncologist 9 Suppl 5 18 30
22. AM Shannon DJ Bouchier-Hayes CM Condron D. Toomey 2005 Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma Br J Cancer 93 2 224 32
23. R Stasi S Amadori TJ Littlewood E Terzoli AC Newland D. Provan 2005 Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns Oncologist 10 7 539 54
24. IJ Hoogsteen WJ Peeters HA Marres PF Rijken FJ van den Hoogen AJ van der Kogel 2005 Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas Radiother Oncol 76 2 213 8
25. SC Martin DD Gagnon L Zhang C Bokemeyer M Van Marwijk Kooy B. van Hout 2003 Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer Pharmacoeconomics 21 16 1153 69
26. K Munstedt M Kovacic M Zygmunt R. Von Georgi 2003 Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer Int J Oncol 23 3 837 43
27. MO Arcasoy X Jiang ZA. Haroon 2003 Expression of erythropoietin receptor splice variants in human cancer Biochem Biophys Res Commun 307 4 999 1007
28. T Sato T Maekawa S Watanabe K Tsuji T. Nakahata 2000 Erythroid progenitors differentiate and mature in response to endogenous erythropoietin J Clin Invest 106 2 263 70
29. M Henke D Mattern M Pepe C Bezay C Weissenberger M Werner 2006 Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24 29 4708 13
30. K Lundholm P Daneryd I Bosaeus U Körner E. Lindholm 2004 Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism and function. A randomized prospetive study Cancer 100 1967 77
31. K Lundholm J Gelin A Hyltander C Lonnroth R Sandstrom G Svaninger 1994 Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors Cancer Res 54 21 5602 6
32. SJ Pocock R. Simon 1975 Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1 103 15
33. GD Demetri JL Gabrilove MV Blasi RJ Hill Jr. J. Glaspy 2002 Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy Clin Breast Cancer 3 1 45 51
34. D Kotasek G Steger W Faught C Underhill E Poulsen AB Colowick 2003 Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study Eur J Cancer 39 14 2026 34
35. E Lindholm P Daneryd U Korner A Hyltander M Fouladiun K. Lundholm 2004 Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients Clin Cancer Res 10 20 6855 64
36. P Kokhaei AO Abdalla L Hansson E Mikaelsson M Kubbies A Haselbeck 2007 Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies Clin Cancer Res 13 12 3536 44
37. S Elliott L Busse MB Bass H Lu I Sarosi AM Sinclair 2006 Anti-Epo receptor antibodies do not predict Epo receptor expression Blood 107 5 1892 5
38. H Axelsson C Lönnroth W Wang E Svanberg K. Lundholm 2005 Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice Angiogenesis 8 4 339 48
39. C Lönnroth M Andersson K. Lundholm 2001 Indomethacin and telomerase activity in tumor growth retardation Int J Oncology 18 929 37
40. C Lönnroth G Svaninger J Gelin C Cahlin B-M Iresjö E Cvetkovska 1995 Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia Int J Oncol 7 1405 13
41. D Cervi AH Truong JS Lee N Sukhai YJ Li A Koki 2004 Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib Oncogene 23 13 2305 14